Drug Profile
Anti-HIV catalytic antibody - Abgenix
Alternative Names: HIV-CALatest Information Update: 23 Feb 2005
Price :
$50
*
At a glance
- Originator Abgenix
- Class Catalytic antibodies
- Mechanism of Action HIV envelope protein gp120 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 30 Jun 2004 Discontinued - Preclinical for HIV infections treatment in USA (Parenteral)
- 30 Nov 2001 Hesed Biomed has been acquired by Abgenix
- 22 Nov 1999 HIV-CA is available for licensing (http://www.hesedbiomed.com)